Cargando…

Melatonin Supplementation and Anthropometric Indices: A Randomized Double-Blind Controlled Clinical Trial

Obesity, as the most common metabolic disorder in the world, is characterized by excess body fat. This study is aimed at determining the effects of melatonin supplementation on body weight, nody mass index (BMI), waist circumference (WC), and body fat mass percentage (BFMP) in people with overweight...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohammadi, Salman, Rastmanesh, Reza, Jahangir, Farzaneh, Amiri, Zohreh, Djafarian, Kurosh, Mohsenpour, Mohammad Ali, Hassanipour, Soheil, Ghaffarian-Bahraman, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8373505/
https://www.ncbi.nlm.nih.gov/pubmed/34423033
http://dx.doi.org/10.1155/2021/3502325
_version_ 1783739955390971904
author Mohammadi, Salman
Rastmanesh, Reza
Jahangir, Farzaneh
Amiri, Zohreh
Djafarian, Kurosh
Mohsenpour, Mohammad Ali
Hassanipour, Soheil
Ghaffarian-Bahraman, Ali
author_facet Mohammadi, Salman
Rastmanesh, Reza
Jahangir, Farzaneh
Amiri, Zohreh
Djafarian, Kurosh
Mohsenpour, Mohammad Ali
Hassanipour, Soheil
Ghaffarian-Bahraman, Ali
author_sort Mohammadi, Salman
collection PubMed
description Obesity, as the most common metabolic disorder in the world, is characterized by excess body fat. This study is aimed at determining the effects of melatonin supplementation on body weight, nody mass index (BMI), waist circumference (WC), and body fat mass percentage (BFMP) in people with overweight or obesity. Thirty eight overweight or class-I obese adult individuals were recruited in the study (8 men and 30 women). Participants prescribed a weight-loss diet and then randomly were allocated to melatonin or placebo groups. Participants received either a 3-milligram melatonin or placebo tablet per day for 12 weeks. In order to assess differences at the significance level of 0.05, repeated measure ANOVA and paired t-test were used. According to the results, a significant reduction was found in participants' body weight, WC, and BMI in both groups (p = 0.001). However, for the last six weeks, significant reductions of these parameters were observed only in the melatonin group (p = 0.01). The BFMP of participants in the melatonin group showed a significant reduction at the end of the study compared to the initial measurements (p = 0.008). Nevertheless, the results of the present study alone are not sufficient to conclude on the effects of melatonin consumption on anthropometric indices, and it seems that further studies are required in this regard.
format Online
Article
Text
id pubmed-8373505
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-83735052021-08-19 Melatonin Supplementation and Anthropometric Indices: A Randomized Double-Blind Controlled Clinical Trial Mohammadi, Salman Rastmanesh, Reza Jahangir, Farzaneh Amiri, Zohreh Djafarian, Kurosh Mohsenpour, Mohammad Ali Hassanipour, Soheil Ghaffarian-Bahraman, Ali Biomed Res Int Research Article Obesity, as the most common metabolic disorder in the world, is characterized by excess body fat. This study is aimed at determining the effects of melatonin supplementation on body weight, nody mass index (BMI), waist circumference (WC), and body fat mass percentage (BFMP) in people with overweight or obesity. Thirty eight overweight or class-I obese adult individuals were recruited in the study (8 men and 30 women). Participants prescribed a weight-loss diet and then randomly were allocated to melatonin or placebo groups. Participants received either a 3-milligram melatonin or placebo tablet per day for 12 weeks. In order to assess differences at the significance level of 0.05, repeated measure ANOVA and paired t-test were used. According to the results, a significant reduction was found in participants' body weight, WC, and BMI in both groups (p = 0.001). However, for the last six weeks, significant reductions of these parameters were observed only in the melatonin group (p = 0.01). The BFMP of participants in the melatonin group showed a significant reduction at the end of the study compared to the initial measurements (p = 0.008). Nevertheless, the results of the present study alone are not sufficient to conclude on the effects of melatonin consumption on anthropometric indices, and it seems that further studies are required in this regard. Hindawi 2021-08-10 /pmc/articles/PMC8373505/ /pubmed/34423033 http://dx.doi.org/10.1155/2021/3502325 Text en Copyright © 2021 Salman Mohammadi et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Mohammadi, Salman
Rastmanesh, Reza
Jahangir, Farzaneh
Amiri, Zohreh
Djafarian, Kurosh
Mohsenpour, Mohammad Ali
Hassanipour, Soheil
Ghaffarian-Bahraman, Ali
Melatonin Supplementation and Anthropometric Indices: A Randomized Double-Blind Controlled Clinical Trial
title Melatonin Supplementation and Anthropometric Indices: A Randomized Double-Blind Controlled Clinical Trial
title_full Melatonin Supplementation and Anthropometric Indices: A Randomized Double-Blind Controlled Clinical Trial
title_fullStr Melatonin Supplementation and Anthropometric Indices: A Randomized Double-Blind Controlled Clinical Trial
title_full_unstemmed Melatonin Supplementation and Anthropometric Indices: A Randomized Double-Blind Controlled Clinical Trial
title_short Melatonin Supplementation and Anthropometric Indices: A Randomized Double-Blind Controlled Clinical Trial
title_sort melatonin supplementation and anthropometric indices: a randomized double-blind controlled clinical trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8373505/
https://www.ncbi.nlm.nih.gov/pubmed/34423033
http://dx.doi.org/10.1155/2021/3502325
work_keys_str_mv AT mohammadisalman melatoninsupplementationandanthropometricindicesarandomizeddoubleblindcontrolledclinicaltrial
AT rastmaneshreza melatoninsupplementationandanthropometricindicesarandomizeddoubleblindcontrolledclinicaltrial
AT jahangirfarzaneh melatoninsupplementationandanthropometricindicesarandomizeddoubleblindcontrolledclinicaltrial
AT amirizohreh melatoninsupplementationandanthropometricindicesarandomizeddoubleblindcontrolledclinicaltrial
AT djafariankurosh melatoninsupplementationandanthropometricindicesarandomizeddoubleblindcontrolledclinicaltrial
AT mohsenpourmohammadali melatoninsupplementationandanthropometricindicesarandomizeddoubleblindcontrolledclinicaltrial
AT hassanipoursoheil melatoninsupplementationandanthropometricindicesarandomizeddoubleblindcontrolledclinicaltrial
AT ghaffarianbahramanali melatoninsupplementationandanthropometricindicesarandomizeddoubleblindcontrolledclinicaltrial